Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09PPU
|
|||
| Drug Name |
CA-170
|
|||
| Synonyms |
3-Aminopyrrolidine dihydrochloride; 103831-11-4; pyrrolidin-3-amine dihydrochloride; 3-Pyrrolidinamine, dihydrochloride; 3-Aminopyrrolidine 2HCl; 3-Aminopyrrolidine diHCl; SCHEMBL555933; ACMC-2099s1; ACMC-2099s3; ACMC-20989g; 3-pyrrolidinamine dihydrochloride; CTK0H7226; DTXSID00583661; MolPort-002-343-989; NJPNCMOUEXEGBL-UHFFFAOYSA-N; 3-Amino-pyrrolidine dihydrochloride; KS-00000JI6; ACT01710; ANW-14978; SBB003982; ( -3-Aminopyrrolidine dihydrochloride; AKOS015844825; VP60158; AM85320; VP60228; TRA0055207; TRA0000843; TRA0097
Click to Show/Hide
|
|||
| Drug Type |
Small molecule immunotherapy
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | ||
| Company |
Curis Lexington, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C4H12Cl2N2
|
|||
| Canonical SMILES |
C1CNCC1N.Cl.Cl
|
|||
| InChI |
1S/C4H10N2.2ClH/c5-4-1-2-6-3-4;;/h4,6H,1-3,5H2;2*1H
|
|||
| InChIKey |
NJPNCMOUEXEGBL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 103831-11-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death 1 ligand 1 (PD-L1) | Target Info | Inhibitor | [1] |
| V-set immunoregulatory receptor (VSIR) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Reactome | PD-1 signaling | |||
| WikiPathways | Costimulation by the CD28 family | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.